Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Vutrisiran Market Grow Over the Forecast Period Based on Its Expected CAGR?

The market size of vutrisiran has seen swift expansion in the recent past. The growth is projected to increase from $0.60 billion in 2024 to $0.68 billion in 2025, at a compound annual growth rate (CAGR) of 12.8%. The significant growth observed in the earlier period can be linked to a growing understanding of hereditary transthyretin amyloidosis, an escalation in clinical trials, a rise in healthcare expenditure, an increase in patient inclination towards non-invasive administration techniques, and a hike in genetic disorder incidences.

The market size for vutrisiran is anticipated to expand significantly in the coming years, reaching a valuation of $1.08 billion by 2029, with a CAGR of 12.4%. This growth during the forecast period can be associated with the growing accessibility of healthcare, increasing occurrences of chronic ailments, heightened investment in R&D, a pronounced emphasis on individualized medicine, and increased disease awareness. Key trends during this projected timeline include progress in combination therapy, the uptake of targeted therapy, advancement in personalized medicine, the rise of digital health technologies, and enhanced development in biotechnology.

What External and Internal Drivers Are Contributing to the Growth of the Vutrisiran Market’s Growth?

The growth of the vutrisiran market is predicted to be buoyed by escalating investments in research and development. Research and development embody the systematic investigation and trial-based improvements to services, products, or processes. Factors contributing to this increase in R&D investment encompass governmental initiatives and funding, the expansion of pharmaceutical and healthcare requirements, sustainability, and environmental issues. Funds allocated for research and development enable pharmaceutical organizations to perform clinical trials, thereby revealing long-term advantages and safety of the drug, resulting in extensive regulatory approvals. Moreover, the evolution of RNA interference (RNAi) technology enhances the accuracy of the drug, minimizes side effects, and boosts patient engagement. For example, Eurostat, a Luxembourg-based statistical authority of the European Union, reported in December 2023 that the European Union’s spending on research and development (R&D) spiked by 6.34% from €331 billion ($361.48 billion) in the last year to €352 billion ($384.42 billion) in 2022. As such, the uptick in research and development investments is fuelling the growth of the vutrisiran market.

Explore Comprehensive Insights Into The Global Vutrisiran Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21320&type=smp

Who Are the Dominant Players Expanding Their Reach in the Vutrisiran Market?

Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc

What Are the Top Trends Shaping the Evolution of the Vutrisiran Market?

In the vutrisiran market, there is a predominant shift towards the creation of ground-breaking therapeutics like subcutaneous RNAi therapeutics. These innovative treatments are designed to offer a more user-friendly and less frequent dosing regimen for managing hereditary transthyretin-mediated (hATTR) amyloidosis. Subcutaneous RNAi therapeutics involve the use of RNA interference technology, which is injected beneath the skin for sustained release, guaranteeing a stable drug level over a period of time. This enhances patient convenience and adherence in managing polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis. For instance, Alnylam Pharmaceuticals, a US-based biopharmaceutical firm, received approval for its vutrisiran (AMVUTTRA) from the Food and Drug Administration (FDA) in June 2022. This medication, designed specifically for adult polyneuropathy patients with hereditary transthyretin-mediated (hATTR) amyloidosis, has proven to be effective in significantly improving neuropathy symptoms and stopping disease progression. In the HELIOS-A Phase 3 study, over half of the patients observed a halt or reversal in their disease symptoms. AMVUTTRA boasts an impressive safety profile with zero drug-related discontinuations or fatalities, and a dosing plan that is likely to enhance patient adherence.

Secure Your Global Vutrisiran Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report

Which Market Segments Are Driving Strategic Growth and Trends in the Vutrisiran Market?

The vutrisiran market covered in this report is segmented –

1) By Drug Class: Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleoside, Other Drug Classes

2) By Route Of Administration: Oral, Injectable, Subcutaneous

3) By Patient Demographics: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Antisense Oligonucleotide: Single-Stranded Antisense Oligonucleotides, Double-Stranded Antisense Oligonucleotides

2) By Nucleic Acids: DNA-based Nucleic Acids, RNA-based Nucleic Acids

3) By Nucleotide: Purine Nucleotides, Pyrimidine Nucleotides

4) By Nucleoside: Purine Nucleosides, Pyrimidine Nucleosides

5) By Other Drug Classes: Peptide-Based Drugs, Protein Therapeutics

Which Regions Are Setting the Pace for Vutrisiran Market Growth?

North America was the largest region in the vutrisiran market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Vutrisiran Market Defined Across Different Regions?

Vutrisiran is a small interfering RNA (siRNA) therapy for hereditary transthyretin-mediated (hATTR) amyloidosis. It silences the transthyretin (TTR) gene, reducing abnormal TTR protein deposits that cause polyneuropathy and organ damage. Vutrisiran helps slow disease progression and improve neurological function, mobility, and quality of life with a longer dosing interval.

Browse Through More Similar Reports By The Business Research Company:

Hepatitis B Virus (HBV) Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Viral Hepatitis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Hepatitis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: